BlueCross BlueShield of South Carolina and BlueChoice[®] HealthPlan of South Carolina

December 2024 Medical Policy Updates

BlueCross BlueShield of South Carolina and BlueChoice HealthPlan frequently revise the medical policies we use to make clinical determinations for a member's coverage. Here are medical policies that have been updated or newly added. A revision history for each policy is included. Please visit the Medical Policies pages of <u>www.SouthCarolinaBlues.com</u> and <u>www.BlueChoiceSC.com</u> regularly to stay informed of these changes and to read any policy in its entirety.

Policy Number	Policy Name	Recent Changes
CAM 60153	Digital Breast Tomosynthesis	ARCHIVED
CAM 40116	Progesterone Therapy as a	ARCHIVED
	Technique To Reduce Preterm	
	Delivery in High-Risk Pregnancies	
CAM 70144	Implantable Cardioverter Defibrillator	Annual review, expanding policy coverage for pediatrics. Also
	(ICD)	updating guidelines, regulatory status, description, rationale
		and references.
CAM 20232	Leadless Cardiac Pacemakers	Annual review, updating policy to include a not medically
		necessary statement for Aveir DR dual chamber pacing
		system. Also updating background, rationale and references.
CAM 20230	Transcatheter Mitral Valve Repair	Annual review, adding policy verbiage for TMViVR. Also
		updating rationale and references and adding codes 0483T
		and 0484T.
CAM 701101	Surgical Treatment of Snoring and	Interim review to remove coverage language regarding
	Obstructive Sleep Apnea Syndrome	mandibular-maxillary advancement surgery and direct reader
		to CAM 041 Orthognathic Surgery. No other changes.
CAM 20226	Percutaneous Left-Atrial Appendage	Annual review, no change to policy intent. Updating rationale
	Closure Devices for Stroke Prevention	and references.
	in Atrial Fibrillation	

Multiple additions to indications for this technology: Frequency of screening in genetic syndromes, Screening for aneurysm in high-risk populations > Bicuspid aortic value • Known aortic diseases (aneurysm, carctation, dissection) • Suspected cerebral vasopasm • Suspected carotid or vertebral artery dissection; secondary to trauma or spontaneous due to weakness of vessel wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to trauma or spontaneous due to weakness of vessel wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoaguitation treatment (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoaguitation resument (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoaguitation resument (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoaguitation voscular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CTI/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculistic Giant cell or takayasu arteritis) with suspected intracenalial and extracenalial involvement (Brain/Neek CTA combo) • Know Moyamoya disease or eversible cerebral vascoonstriction with any new or changing neurological signs or symptoms (Brain CTA/Fria Crombo) • Kone MN3 sort cannot be performed also adding purpose, contraindicated or cannot be performed also adding purpose, cont	CAM 727	CT Angiography, Head/Brain	Annual review, policy reformatted for clarity and consistency.
aneurysm in high-risk populations • Bicuspid aortic valve • Known aortic diseases (aneurysm, coarctation, dissection) • Suspected cerbral vasopsam • Suspected carotid or vertebral artery dissection; secondary to trauma or spontaneous due to weakness of vessel wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation and/or to trauma or spontaneous due to weakness of vessel wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoaguidon treatment (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoaguidon treatment (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoaguidon treatment (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoaguidon treatment (already in combo) • Follow-up of known arotid or vertebral artery dissection with any neov changing neurological signs or symptoms in the setting of an undrehying systemic disease with abnormal inflammatory markers or autoimmune antibodies (grain CTA/CT combo) • Know Moyamoy a disease or eversible cerebral vasoculitis based on neurological signs or symptoms in the setting of an undrehying systemic disease with abnormal inflammatory markers or autoimmune antibodies (grain CTA/CT combo) • When MRI is contraindicated or cannot be performed sits adong purpose, contraindicated or cannot be performed sits adding purpose, contraindicated or cannot be performed sits adding purpose, contraindicated, also for clarity and consistency. Purpose statement and contraindication/pref			Multiple additions to indications for this technology:
Known aortic diseases (aneurysm, coarctation, dissection) • Suspected cerebral vasospasm • Suspected carotid or vertebral artery dissection; secondary to trauma or spontaneous due to weakness of vessel wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to trauma or spontaneous due to weakness of vessel wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticogulation treatment (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticogulation treatment (already in combo) • Horner's syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section • Genetic syndromes and rare disease section • Ferfactory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH + Large vessel vasocitis (Giant cell or takayasu arterits) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo Suspected primary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed 4 suspected primary CNS vasculitis based on neurological signs and symptoms with completed in			Frequency of screening in genetic syndromes, Screening for
Suspected cerebral vasospasm - Suspected carotid or vertebral artery dissection; secondary to trauma or spontaneous due to weakness of vessel wall (already in combo) - Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to trauma or spontaneous due to weakness of vessel wall (already in combo) - Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoagulation treatment (already in combo) + Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoagulation treatment (already in combo) + Horner's syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section • Genetic syndromes and rare disease section • Refractory trigeminal neuralgia or hemificali apsam when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH + Large vessel vasculitis (Giant Cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo - Suspected primary CNS vasculits based on neurological signs or symptoms in the setting of an underlying systemic disease with abnoral inflammatory markers or autoimmum antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed 4 subgest derivanty. CNS vasculits based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) whe			aneurysm in high-risk populations • Bicuspid aortic valve •
vertebral artery dissection; secondary to trauma or spontaneous due to weakness of vessel wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to trauma or spontaneous due to weakness of vessel wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoagulation treatment (already in combo) • Horner's syndrome, non-central (micois, ptosis, and anhidrosisalso in combo section • Genetic syndromes and rare disease section. • Refractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in a nacute setting with high suspiciton of SAH Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vascounstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed 450 adding purpose, contraindication/sprefermed studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, minor revisions made. Adding pediatric 			Known aortic diseases (aneurysm, coarctation, dissection) •
Spontaneous due to weakness of vessel wall (already in combo) - Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to trauma or spontaneous due to weakness of vessel wall (already in combo) - Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoagulation treatment (already in combo) + Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoagulation treatment (already in combo) + Horner's syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section - Senetic syndromes and rare disease section. • Refractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayau arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CM vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory makers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindications/preferred studies. Updating rationale/background and references. <td< th=""><th></th><th></th><th>Suspected cerebral vasospasm • Suspected carotid or</th></td<>			Suspected cerebral vasospasm • Suspected carotid or
combol • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to trauma or spontaneous due to weakness of vessel wall (already in combol • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoagulation treatment (already in combo) • Horner's syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section • Genetic syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section • Genetic syndromes and rare disease section. • Refractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headche >6 hours after onset in an acute setting with high suspicion of SAH Large vessel vascultis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial inolvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo) Suspected primary CNS vasculitis based on neurological signs or symptoms (Brain CTA/Brain CT combo) • Karis CTA/Brain CT combo • Kursen CTA/Brain CT combo • Suspected primary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemi disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed 4 suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT Combo) when MRI is contraindications/preferred studies. Updating rationale/background and ref			vertebral artery dissection; secondary to trauma or
dissection within 3-6 months for evaluation of recanalization and/or to trauma or spontaneous due to weakness of vessel wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoagulation treatment (already in combo) • Horner's syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section • Genetic syndromes and rare disease section. • Refractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH + Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed - Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding purpose, contraindication/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, minor revisions made. Adding pediatiric neurologist as specialty allowed to perform testing and decreased additional testing			spontaneous due to weakness of vessel wall (already in
and/or to trauma or spontaneous due to weakness of vessel wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoagulation treatment (already in combo) • Horner's syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section • Genetic syndromes and rare disease section • Netractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CTCTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is comtraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs or symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is completed infectious/inflammatory			combo) • Follow-up of known carotid or vertebral artery
wall (already in combo) • Follow-up of known carotid or vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoagulation treatment (already in combo) • Horner's syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section • Genetic syndromes and rare disease section. • Refractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CTCTA section Thunderclap headache > 6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs or symptoms (IR and CTA/CT combo) when KRI is contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding purpose, contra			dissection within 3-6 months for evaluation of recanalization
Vertebral artery dissection within 3-6 months for evaluation of recanalization and/or to guide anticoagulation treatment (already in combo) • Horner's syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section • Genetic syndromes and rare disease section. • Refractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed 4 Suspected primary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed 4 Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CA			and/or to trauma or spontaneous due to weakness of vessel
Applied Behavioral Analysis Servicesof recanalization and/or to guide anticoagulation treatment (already in combo) • Horner's syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section • Genetic syndromes and rare disease section. • Refractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours a fiter onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performated to clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Ungose statement and contraindication/preferred studies statement added, also for clarity and consistency. Ungose statement added, also if clarity and consistency. Ungose statement added, also if clarity and consistency. Ungose statement added, also if clarity and consistency			wall (already in combo) • Follow-up of known carotid or
(already in combo) • Horner's syndrome, non-central (miosis, ptosis, and anhidrosis also in combo section • Genetic syndromes and rare disease section. • Refractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed + Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating reformate studies statement added, also for clarity and consistency. Updating references.CAM 725CT Upper ExtremityAnnual review, no change to policy intert, policy being reformated for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			vertebral artery dissection within 3-6 months for evaluation
ptosis, and anhidrosis also in combo section • Genetic syndromes and rare disease section. • Refractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformed also adding purpose, contraindicatios/preferred studies. Updating rationale/background and references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			of recanalization and/or to guide anticoagulation treatment
Syndromes and rare disease section. • Refractory trigeminal neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding nupose, contraindicated or cannot			(already in combo) • Horner's syndrome, non-central (miosis,
neuralgia or hemifacial spasm when done for surgical evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding pur			ptosis, and anhidrosis also in combo section • Genetic
evaluation • Note: For remote strokes with no prior vascular imaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformated for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding ped			syndromes and rare disease section. • Refractory trigeminal
CAM 725CT Upper Extremityimaging, imaging can be considered based on location/type of stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			neuralgia or hemifacial spasm when done for surgical
Stroke and documented potential to change management • To combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformated for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			evaluation • Note: For remote strokes with no prior vascular
CAM 725CT Upper ExtremityTo combo CT/CTA section Thunderclap headache >6 hours after onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			imaging, imaging can be considered based on location/type of
Applied Behavioral Analysis Servicesafter onset in an acute setting with high suspicion of SAH • Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			stroke and documented potential to change management •
Large vessel vasculitis (Giant cell or takayasu arteritis) with suspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding purpose, contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis Services under the priority and consistency. Updating requirement from 2 to 1.			To combo CT/CTA section Thunderclap headache >6 hours
CAM 725CT Upper ExtremitySuspected intracranial and extracranial involvement (Brain/Neck CTA combo) • Know Moyamoya disease or eversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis Services uAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			after onset in an acute setting with high suspicion of SAH $ullet$
CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformated for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			Large vessel vasculitis (Giant cell or takayasu arteritis) with
CAM 725CT Upper Extremityeversible cerebral vasoconstriction with any new or changing neurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis Services and contraindicational testing requirement from 2 to 1.			suspected intracranial and extracranial involvement
Applied Behavioral Analysis Servicesneurological signs or symptoms (Brain CTA/Brain CT combo • Suspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			(Brain/Neck CTA combo) • Know Moyamoya disease or
CAM 725CT Upper ExtremitySuspected secondary CNS vasculitis based on neurological signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			eversible cerebral vasoconstriction with any new or changing
signs or symptoms in the setting of an underlying systemic disease with abnormal inflammatory markers or autoimmune antibodies (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed • Suspected primary CNS vasculitis based on neurological signs and symptoms with completed infectious/inflammatory lab work-up (Brain CTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			neurological signs or symptoms (Brain CTA/Brain CT combo •
CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specially allowed to perform testing and decreased additional testing requirement from 2 to 1.			Suspected secondary CNS vasculitis based on neurological
Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform to 1.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform to 1.			signs or symptoms in the setting of an underlying systemic
CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformated for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			disease with abnormal inflammatory markers or autoimmune
CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformated for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			antibodies (Brain CTA/CT combo) when MRI is
CAM 725CT Upper ExtremityCTA/CT combo) when MRI is contraindicated or cannot be performed also adding purpose, contraindications/preferred studies. Updating rationale/background and references.CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			contraindicated or cannot be performed • Suspected primary
CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			CNS vasculitis based on neurological signs and symptoms with
CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis Services (LAM 387)Annual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			completed infectious/inflammatory lab work-up (Brain
CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis Services under the statement and decreased additional testing requirement from 2 to 1.			CTA/CT combo) when MRI is contraindicated or cannot be
CAM 725CT Upper ExtremityAnnual review, no change to policy intent, policy being reformatted for clarity and consistency. Purpose statement and contraindication/preferred studies statement added, also for clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			performed also adding purpose, contraindications/preferred
CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			studies. Updating rationale/background and references.
CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.	CAM 725	CT Upper Extremity	Annual review, no change to policy intent, policy being
CAM 387Applied Behavioral Analysis Servicesfor clarity and consistency. Updating references.CAM 387Applied Behavioral Analysis ServicesAnnual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			reformatted for clarity and consistency. Purpose statement
CAM 387 Applied Behavioral Analysis Services Annual review, minor revisions made. Adding pediatric neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			
neurologist as specialty allowed to perform testing and decreased additional testing requirement from 2 to 1.			for clarity and consistency. Updating references.
decreased additional testing requirement from 2 to 1.	CAM 387	Applied Behavioral Analysis Services	Annual review, minor revisions made. Adding pediatric
			neurologist as specialty allowed to perform testing and
CAM 338 Skilled Nursing Facility Annual review, no change to policy intent.			
	CAM 338	Skilled Nursing Facility	Annual review, no change to policy intent.

CAM 90102	Evaluation of Hearing Impairment	Annual review, no change to policy intent.
CAM 175	Fractional Flow Reserve CT	Annual review, no change to policy intent.
CAM 201103	D1103Trigger Point and Tender PointAnnual review, no change to policy intent.Injections	
CAM 30103	Quantitative Electroencephalography as a Diagnostic Aid for Attention- Deficit/Hyperactivity Disorder	Annual review, no change to policy intent.
CAM 392	Sacroiliac Joint Fusion	Annual review, no change to policy intent.
CAM 701173	Axillary Reverse Mapping for Breast Cancer-Related Lymphedema	Annual review, no change to policy intent. Updating rationale and references.
CAM 701155	Functional Endoscopic Sinus Surgery for Chronic Rhinosinusitis	Annual review, no change to policy intent. Updating rationale and references.
CAM 70119	Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence	Annual review, no change to policy intent.
CAM 70150	Placental and Umbilical Cord Blood as a Source of Stem Cells	Annual review, no change to policy intent.
CAM 706	CT Angiography, Abdomen	Annual review, policy updated for clarity and consistency. Separated aortic syndromes, EVAR studies clarified order in which studies would be ordered, renal artery stenosis updated, adding genetic syndromes and tumors section. Combination section adjust for clarity. Also updating rationale and references.
CAM 726	CT Angiography, Upper Extremity	Annual review, policy updated for clarity and consistency, adding evaluation of tumor, genetic syndromes, rare diseases and contraindications and preferred studies. Also updating rationale and references.
CAM 728	Abdominal Aorta CT Angiography with Lower Extremity Runoff	Annual review, policy updated for clarity and consistency, combination studies, genetic syndromes, rare disease and contraindications/preferred studies section added. Also updating rationale and references. Policy title updated.
CAM 742	CT Head/Brain	Annual review, policy updated for clarity and consistency, updated Cancer section, vertigo with progressive unilateral hearing loss or tinnitus, known Moyamoya disease, thunderclap headache criteria. Also updating rationale and references.
CAM 751	Brain PET Scan	Annual review, policy updated for clarity and consistency, Amyloid PET indications moved to oncologic PET guidelines, updating indications for known brain tumor or cancer. Also updating rationale and references.
CAM 80118	Lysis of Epidural Adhesions	Annual review, no change to policy intent.
CAM 90305	Corneal Topography/Computer- Assisted Corneal Topography/Photokeratoscopy	Annual review, no change to policy intent. Updating regulatory status.

CAM 748	CT Bone Density Study	Annual review, no change to policy intent. Replacing
		"description" with "background", adding general information
		statement for clarity and consistency. Updating references
		and reference numbers through policy.
CAM 756	Hyperthermia With Radiation	Annual review, no change to policy intent.
CAM 758	Radiation Therapy for Non-Cancerous	Annual review, no change to policy intent.
	Conditions	
CAM 10101	Air Fluidized Beds	Annual review, no change to policy intent.
CAM 70177	Total Ankle Replacement	Annual review, no change to policy intent.
CAM 70198	Minimally Invasive Hip and Knee	Annual review, no change to policy intent.
	Arthroplasty	
CAM 701117	Arthroscopic Debridement and	Annual review, no change to policy intent.
	Lavage as Treatment for	
	Osteoarthritis of the Knee	
CAM 716	CT Abdomen and Pelvis	Annual review, no changes made.
CAM 176	Telehealth	Updated coding with CPT codes 98000 - 98007 with an
		effective date of 01/01/2025. No other changes.
CAM 133	Diabetes Mellitus Testing	Added Code CPT 82947 to coding section. No other change
		made.
CAM 335	Biochemical Markers of Alzheimer	Updated coding with CPT codes 82233 and 82234 with an
	Disease and Dementia	effective date of 01/01/2025. No other changes.
CAM 70195	Radiofrequency Ablation of	Updated coding with CPT codes 60660 and 60661 with an
	Miscellaneous Solid Tumors Excluding	effective date of 01/01/2025. No other changes.
	Liver Tumors	
CAM 80161	Focal Treatments for Prostate Cancer	Updated coding with CPT codes 55881 and 55882 with an
		effective date of 01/01/2025. No other changes.
CAM 109	Preventive Services for Non-	Updated CPT code 90661 updated Age Group to Both. No
	Grandfathered (PPACA) Plans:	other changes.
	Immunizations	
CAM 322	Immune Cell Function Assay	Moving annual review to January 2025.
CAM 378	Coronary Artery Calcium Scoring by	Annual review, policy updated for clarity and consistency
	Electron-Beam Tomography (EBCT)	including adding AUC scoring, adding clarifying statement
	OR Non-Contrast Coronary Computed	that this test is not to be utilized for symptomatic patients.
	Tomography (Non-Contrast CCT)	Also updating rationale and references.
CAM 709	MRI Lumbar Spine	Annual review, policy reformatted for clarity and consistency,
		adding contraindications and preferred studies section,
		updating description, rationale and references.
CAM 711	CT Pelvis	Annual review, policy reformatted for clarity and consistency.
		Updating combination studies, clarification contraindications
		vs MRI and CT use. Also updating rationale and references.
CAM 713	CT Lumbar Spine	Annual review, no change to policy intent. Policy reformatted
		for clarity and consistency. Adding contraindications/
		preferred studies, updating references.

CAM 714	MRI Pelvis	Annual review, updating policy for clarity and consistency
		including uses of fetal MRI and Pelvis MRI, gynecologic uses
		updated, prostate cancer, known malignancies and
		inflammation/infections sections reorganized. Genetic and
		rare disease section added and combination studies updated.
		Also updating rationale and references.
CAM 715	CT Lower Extremity (Ankle, Foot, Hip	Annual review, no change to policy intent but policy verbiage
	or Knee)	being reformatted for clarity and consistency. Removing
		verbiage regarding sonogram for leg length. Adding special
		note, Contraindication and preferred for clarity and
		consistency. Updating references.
CAM 717	CT Abdomen CT	Annual review, policy updated for clarity and consistency,
		genetics, malignancy and organ sections reorganized,
		renal/kidney disease updated, adding post embolization
		imaging, adding including adding CPT 0722T, adding
		contraindications and preferred studies section, updating
		combination studies. Also updating rationale and references.
CAM 744	MRI Brain (Includes Internal Auditory	Annual review, policy updated for clarity and consistency.
	Canal)	Adding - Genetic syndromes and rare disease section-
		reorganized indications - Note: Vessel wall MRI (ordered as
		Brain MRI) can also be performed in the evaluation of
		vasculitides - PML suspected or known to the infectious or
		inflammatory disease section And updated Brain MRI for
		Known Cancer sections (initial staging, restaging and
		surveillance) - Vertigo with progressive unilateral hearing loss
		or tinnitus Horner's syndrome with symptoms localizing the
		lesion to the central nervous system (Brain/Cervical MRI
		Combo) - Known Moyamoya disease or eversible cerebral
		vasoconstriction with any new or changing neurological signs
		or symptoms (also to (Brain MRA /MRI combo) - Suspected
		secondary CNS vasculitis based on neurological signs or
		symptoms in the setting of an underlying systemic disease
		with abnormal inflammatory markers or autoimmune
		antibodies (Brain MRA /MRI combo) - Suspected primary CNS
		vasculitis based on neurological signs and symptoms with
		completed infectious/inflammatory lab work-up ((Brain MRA
		/MRI combo)) - Giant cell arteritis with suspected intracranial
		and extracranial involvement (Brain MRA /Neck/ Brain MRI
		combo)) Clarified - Updated pediatric seizure section
		Treatment of Alzheimer's disease with anti-amyloid- β
		monoclonal antibodies - baseline and surveillance imaging as
		per FDA labeling. Also updating description, references and
		combination section. Adding purpose.

CAM 745	Temporal Bone, Mastoid, Orbits,	Annual review, policy updated for clarity and consistency
	Sella, Internal Auditory Canal CT	including adding contraindications and preferred studies.
		Adding indications for pulsatile tinnitus. Also updating
		rationale and references.
CAM 763	Heart (Cardiac) PET With CT for	Annual review, policy updated for clarity and consistency,
	Attenuation	including adding AUC scores and calcium score. Also updating
		rationale and references.
CAM 766	Brain (Head) MRS	Annual review, updating policy for clarity and consistency,
		adding contraindications and preferred studies and pediatric
		metabolic disorders section. Also updating rationale and
		references.
CAM 053	Orthodontic Treatment	Annual review, no change to policy intent.
CAM 094	Women's Preventive Services	Annual review, no change to policy intent.
CAM 20102	Dynamic Posturography	Annual review, no change to policy intent.
CAM 201104	Vestibular Function Testing	Annual review, no change to policy intent. Updating
		references.
CAM 252	Bowel Management Devices	Annual review, no change to policy intent.
CAM 389	Lumbar Artificial Disc Replacement	Annual review, no change to policy intent.
CAM 60158	Endobronchial Ultrasound for	Annual review, no change to policy intent. Updating
	Diagnosis and Staging of Lung Cancer	regulatory status, table 12, and reference 16.
CAM 701	MR Angiography Upper Extremity	Annual review, no change to policy intent. Adding
		contraindications/preferred studies for clarity and
		consistency. Updating references and reference numbers.
CAM 701109	Magnetic Resonance — Guided	Adding code 61715 effective 01012025.
	Focused Ultrasound	
CAM 701122	Electromagnetic Navigation	Annual review, no change to policy intent. Updating rationale,
	Bronchoscopy	references and HCPCS coding.
CAM 701133	Microwave Tumor Ablation	Annual review, no change to policy intent. Updating rationale and references.
CAM 701135	Surgical and Ablative Treatments for	Annual review, no change to policy intent. Updating rationale
	Chronic Headaches	and references.
CAM 701158	Balloon Dilation of the Eustachian	Annual review, no change to policy intent. Updating
	Tube	regulatory status, rationale, references and HCPCS coding.
CAM 701175	Temporarily Implanted Nitinol Device	Adding codes 53865, 53866 effective 01012025.
	(iTind) for Benign Prostatic	
	Hyperplasia	
CAM 70172	Percutaneous Intradiscal	Annual review, no change to policy intent. Updating
	Electrothermal Annuloplasty,	regulatory status and references.
	Radiofrequency Biacuplasty	
CAM 70120	Vagus Nerve Stimulation	Annual review, no change to policy intent. Updating rationale,
		references and HCPCS coding.
CAM 70302	Allogeneic Pancreas Transplant	Annual review, no change to policy intent. Updating pancreas
		specific guidelines, rationale, and references.
CAM 70306	Liver Transplant and Combined Liver-	Annual review, no change to policy intent. Updating rationale,
	Kidney Transplant	references and CPT coding.

CAM 720	MRI MRCP MRE MRU Abdomen	Annual review, policy updated for clarity and consistency, genetics section and malignancy reorganized, organ section reorganized, polycystic kidney section updated, adding post embolization imaging and contraindications and preferred studies added. Also updating description, rationale and references. Adding CPT 0722T.
CAM 721	Lower Extremity MRI (Foot, Ankle, Knee, Leg or Hip MRI)	Annual review, no change to policy intent, but, policy reformatted for clarity and consistency. Adding special note, contraindication/preferred for clarity and consistency. Updating references.
CAM 757	Neutron Beam Therapy (NBT)	Annual review, no change to policy intent.
CAM 761	Functional MRI Brain	Annual review, no change to policy intent. Adding contraindications/preferred studies section, and updating references and reference numbers throughout policy.
CAM 80164	Home Non-Invasive Positive Airway Pressure Devices for the Treatment of Respiratory Insufficiency and Failure	Annual review, no change to policy intent. Updating rationale and references.
CAM 701170	Laser Interstitial Thermal Therapy for Neurological Conditions	Annual review, no change to policy intent. Updating regulatory status, rationale and references.
CAM 701143	Responsive Neurostimulation for the Treatment of Refractory Focal Epilepsy	Annual review, no change to policy intent. Updating rationale and references.
CAM 701132 CAM 701100	Transcatheter Aortic-Valve Implantation for Aortic Stenosis Bone Morphogenetic Protein	Annual review, policy and guidelines updated: For TAVI and VIV TAVI, the criterion of left ventricular ejection fraction greater than 20% was removed. A statement Was Added For consideration of individuals who may be at high risk of open surgery but no demonstrated on Society of Thoracic Surgeons risk score, 'Individual is considered at increased surgical risk for an open surgery but no demonstrated on Society of Thoracic Surgeons risk score, 'Individual is considered at increased surgical risk for a open surgery (eg, repeat sternotomy) due to a history of congenital vascular anomalies AND/OR has a complex intrathoracic surgical history, as documented by at least 2 cardiovascular specialists (including a Cardiac surgeon)'. Also updating description, regulatory status, rationale and references. Annual review, no change to policy intent. Updating rationale
CAM 90308	Dhotodynamic Thorany for Choroidal	and references.
	Photodynamic Therapy for Choroidal Neovascularization	Annual review, no change to policy intent. Updating references and HCPS coding.
CAM 80108	Photodynamic Therapy for Choroidal Neovascularization	Annual review, no change to policy intent.
CAM 70305	Small Bowel/Liver and Multivisceral Transplant	Annual review, no change to policy intent. Updating references.
CAM 70301	Kidney Transplant	Annual review, no change to policy intent. Updating background, guidelines, rationale and references.

CAM 747	Myocardial Perfusion Imaging (Nuc	Annual review, policy updated for clarity and consistency
	Card)	including adding AUC scoring, anginal symptoms verbiage
	,	updated, new guidelines for stress testing within the last 12
		months. Also updating rationale and references.
CAM 70198	Minimally Invasive Hip and Knee	Annual review, no change to policy intent.
	Arthroplasty	
CAM 70177	Total Ankle Replacement	Annual review, no change to policy intent.
CAM 70103	Implantable Bone-Conduction and	Annual review, no change to policy intent. Updating rationale,
	Bone-Anchored Hearing Aids	references and CPT coding.
CAM 10101	Air Fluidized Beds	Annual review, no change to policy intent.
CAM 253	Surgical Treatments for Lymphedema and Lipedema	Annual review, no change to policy intent.
CAM 212	Intracardiac Ischemia Monitoring	Annual review, no change to policy intent.
CAM 050	Daily Hemodialysis and Hemodialysis	Annual review, no change to policy intent.
	in the Home Setting	
CAM 377	Percutaneous Electrical Nerve Field	Interim review to expand age range to 8- 21 years. No other
	Stimulation for Functional Abdominal	changes.
	Pain Disorders	
CAM 391	Low-Dose CT for Lung Cancer	Annual review, no change to policy intent. Updating
	Screening	references and Lung Rads table, policy reformatted for clarity
		and consistency.
CAM 70107	Electrical Bone Growth Stimulation of	Annual review, no change to policy intent. Updating rationale
	the Appendicular Skeleton	and references.
CAM 750	CT Chest (Thorax)	Annual review, policy reformatted for clarity and consistency
		updating: Lung Cancer screening is consistent with Cancer
		society • Lung nodules sections was clarified for size and
		follow up studies • Infections and inflammation section
		added to incorporate indications within the GL that were
		alone and added in sarcoidosis • Reorganized the malignancy
		section to follow the abdomen GLs; for known malignancy
		Initial staging was broad, Restaging gave the situations not
		reasonable, and surveillance was each identified with
		timelines for acceptable studies • Genetic Syndromes and
		Rare Diseases was added/adjusted. • Combination Studies
		were expanded upon to coincide with other
		guidelines/combination studies. Also adding purpose,
CANA 740		contraindications/preferred studies, rationale and references.
CAM 749	CT Angiography, Chest (Noncoronary)	Annual review, policy reformatted for clarity and consistency.
		Added Genetics and Rare Diseases, Evaluation of Tumor,
		Contraindications and Preferred Studies section. Updating references.
CAM 710	MPI Thoracic Spino	
	MRI Thoracic Spine	Annual review, reformatting policy for clarity and consistency, also adding contraindications and preferred studies, updating
		combination studies, adding genetic and rare disease section,
		updating rationale and references.
		משמנוווצ ומנוטוומוב מווט ופופופוונפג.

CAM 393	Heart (Cardiac) PET	Annual review with reformatting of policy for clarity and
		consistency, adding clinical reasoning statements with AUC
		scoring. Also updating rationale, references and
		abbreviation/acronym list.
CAM 718	Upper Extremity MRI	Annual review, no change to policy intent. Updating policy for
		clarity and consistency. Adding special note and
		contraindications/preferred studies for clarity and
		consistency. Updating references.
CAM 719	MRI Heart	Annual review, policy reformatted for clarity and consistency
		including adding AUC scores and combination studies section.
		Also updating rationale and references.
CAM 746	Sinus Maxillofacial CT	Annual review, updating policy for clarity and consistency,
		adding contraindications and preferred studies adding
		verbiage regarding bone marrow transplant, clarifying
		anosmia indication. Also updating description, rationale and
		references.